These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 23030295)

  • 1. Preventing cardiovascular events with angiotensin II receptor blockers: a closer look at telmisartan and valsartan.
    Volpe M
    Expert Rev Cardiovasc Ther; 2012 Aug; 10(8):1061-72. PubMed ID: 23030295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property.
    Yamagishi S; Takeuchi M
    Med Hypotheses; 2005; 64(3):476-8. PubMed ID: 15617852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy.
    Galle J; Schwedhelm E; Pinnetti S; Böger RH; Wanner C;
    Nephrol Dial Transplant; 2008 Oct; 23(10):3174-83. PubMed ID: 18450829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and duration of action of the four selective angiotensin II subtype 1 receptor blockers, losartan, candesartan, valsartan and telmisartan, in patients with essential hypertension determined by home blood pressure measurements.
    Nishimura T; Hashimoto J; Ohkubo T; Kikuya M; Metoki H; Asayama K; Totsune K; Imai Y
    Clin Exp Hypertens; 2005 Aug; 27(6):477-89. PubMed ID: 16081340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic review and meta-analysis of telmisartan versus valsartan in the management of essential hypertension.
    Zheng Z; Lin S; Shi H
    J Clin Hypertens (Greenwich); 2010 Jun; 12(6):414-21. PubMed ID: 20591086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A meta-analysis of randomized trials of telmisartan vs. valsartan therapy for blood pressure reduction.
    Takagi H; Niwa M; Mizuno Y; Goto SN; Umemoto T;
    Hypertens Res; 2013 Jul; 36(7):627-33. PubMed ID: 23344134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period.
    White WB; Lacourciere Y; Davidai G
    Am J Hypertens; 2004 Apr; 17(4):347-53. PubMed ID: 15062889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective, randomized, open-label trial comparing telmisartan 80 mg with valsartan 80 mg in patients with mild to moderate hypertension using ambulatory blood pressure monitoring.
    Littlejohn T; Mroczek W; Marbury T; VanderMaelen CP; Dubiel RF
    Can J Cardiol; 2000 Sep; 16(9):1123-32. PubMed ID: 11021956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of the angiotensin II receptor blockers telmisartan versus valsartan in combination with hydrochlorothiazide: a large, confirmatory trial.
    White WB; Murwin D; Chrysant SG; Koval SE; Davidai G; Guthrie R
    Blood Press Monit; 2008 Feb; 13(1):21-7. PubMed ID: 18199920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of renin-angiotensin system (RAS) blockers on cardiovascular and renal outcomes in patients with type 2 diabetes.
    Cao Z; Cooper ME
    Acta Diabetol; 2012 Aug; 49(4):243-54. PubMed ID: 21947383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of telmisartan 80 mg and valsartan 160 mg on ambulatory blood pressure in patients with essential hypertension.
    White WB; Lacourciere Y
    J Hypertens; 2004 Oct; 22(10):2035-6; author reply 2036-8. PubMed ID: 15361777
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical experience with angiotensin receptor blockers with particular reference to valsartan.
    Chrysant SG; Chrysant GS
    J Clin Hypertens (Greenwich); 2004 Aug; 6(8):445-51. PubMed ID: 15308883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences.
    Miura Y; Yamamoto N; Tsunekawa S; Taguchi S; Eguchi Y; Ozaki N; Oiso Y
    Diabetes Care; 2005 Mar; 28(3):757-8. PubMed ID: 15735228
    [No Abstract]   [Full Text] [Related]  

  • 14. ADMA and oxidative stress may relate to the progression of renal disease: rationale and design of the VIVALDI study.
    Böger RH; Schwedhelm E; Maas R; Quispe-Bravo S; Skamira C
    Vasc Med; 2005 Jul; 10 Suppl 1():S97-102. PubMed ID: 16444875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypertension therapy and cardiovascular protection. Effects of angiotensin II receptor block with Valsartan.
    Sestito A
    Eur Rev Med Pharmacol Sci; 2011 Nov; 15(11):1247-55. PubMed ID: 22195356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction of proteinuria with angiotensin receptor blockers.
    Galle J
    Nat Clin Pract Cardiovasc Med; 2008 Jul; 5 Suppl 1():S36-43. PubMed ID: 18580865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Telmisartan and valsartan].
    Perspect Infirm; 2013; 10(5):63. PubMed ID: 24358681
    [No Abstract]   [Full Text] [Related]  

  • 19. ARBs for cardiovascular and renal protection in high-risk patients.
    Aalbers J
    Cardiovasc J Afr; 2011; 22(4):224. PubMed ID: 21881697
    [No Abstract]   [Full Text] [Related]  

  • 20. Choosing an angiotensin-receptor blocker: blood pressure lowering, cardiovascular protection or both?
    Neldam S
    Future Cardiol; 2010 Jan; 6(1):129-35. PubMed ID: 20014992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.